

Update Note

**BUY**  
TP: INR 770

# JUBILANT INGREVIA

*When Specialty meets value*

June 9<sup>th</sup>, 2021

Vinit Gala, CFA  
Analyst  
Vinit.gala@mnclgroup.com

# INVESTMENT THESIS



We initiated on Jubilant Ingrevia ('Ingrevia') on March 18th, 2021 (note) at INR 240 per share, since then the stock is up >2.4x in less than 4 months! It still trades at ~11x FY23E EV/EBITDA, given the visibility on improving profile and robust pricing environment we believe there is room for further re-rating. Ingrevia came out with a robust set for Q4FY21 on the back of pricing in Acetic Anhydride and Ethyl Acetate (LS Chem EBITDA 19% vs 4% YoY). Demand side disruption in Acetyls is likely to continue over short term. On Spec Chem the growth was led by CDMO, Q3FY22 to see commercialisation of Diketene products – a big trigger. We believe Ingrevia's transition to Specialty remains underappreciated with >70% of EBITDA contribution from non-commoditised segments. We thus revise our Mar-22 target price from INR 420 in base case to INR 770 valuing at 15x EV/EBITDA, which implies 35% upside on the CMP. Our Bull / Bear case TP is at INR 1015 and INR 450 respectively.

BBG code	JUBLINGRE: IN
CMP	INR 573
52 W (H/L)	INR 612 / 214
Target Price	INR 770
Upside	35%



## Q4FY21 results were led by robust performance in Acetyls; Other segments also encouraging

- Q4FY21 sales were up 31% YoY; led by LSChem (up 46% YoY) while Spec Chem / Nutrition were up 17% / 22% respectively. Margin expansion were led by robust pricing environment in LSChem (19% vs 4% in Q4FY20).
- Pricing are expected to sustain over short-term before reverting to normalised base. Acetic acid prices remain flat on annual base. Spec Chem sales were on the back of new CDMO projects while Animal Nutrition and Vitamin B3 prices supported Nutrition.

## Transition to Specialty in underappreciated; >70% of EBITDA from Specialty

- Commodity sales has reduced from 60% in FY19 to 46% in FY23E further >70% EBITDA is contributed from non-commoditised business
- INR 650crs of INR 900crs in new capex is earmarked towards non-commoditised business. Of Which Diketene to be live in Q3FY22 while CDMO is gaining traction amongst agrochemical clients

## Faster ramp-up in Spec Chem to improve business profile; deserving of higher multiples

- Ramp up of Diketene and CDMO business is faster than anticipated. New capex initiatives into superior segments such as Diketene, CDMO, Pre-mixes to improve its overall margins profile.
- Since our initiation at INR 240 per share, the stock is up more than 2.4x in less than 4 months, however still trades at ~11x FY23E EV/EBITDA, we thus believe there is still room for further re-rating.
- On account of the above, we believe Ingrevia has sufficient room to grow its profitability and improving business profile is deserving of higher multiples. We thus revise our Mar-22 target price from INR 420 in base case to INR 770 valuing at 15x EV/EBITDA, which implies 35% upside on the CMP. Our Bull / Bear case TP is at INR 1015 and INR 450 respectively.

P&L (INR in Crs)	FY21	FY22E	FY23E
<b>Revenue</b>	<b>3492</b>	<b>4020</b>	<b>4620</b>
- Spec Chem	1,124	1,349	1,646
- Nutrition	630	725	833
- LS Chem	1,738	1,947	2,141
<b>EBITDA</b>	<b>613</b>	<b>761</b>	<b>840</b>
EBITDA Margin %	18%	19%	18%
<b>PAT</b>	<b>317</b>	<b>423</b>	<b>468</b>
PAT Margin %	9%	11%	10%
EPS	19.8	26.5	29.4

Particulars	EBITDA (INR Crs)	EV/EBITDA (x)	Target Price (INR)	Upside on CMP
<b>Bull Case</b>	<b>912</b>	<b>18</b>	<b>1015</b>	<b>77%</b>
Base Case	840	15	770	35%
<b>Bear Case</b>	<b>746</b>	<b>10</b>	<b>450</b>	<b>-21%</b>


Source: Company, MNCL Research

Vinit Gala, CFA  
Vinit.gala@mnclgroup.com




# TRANSITION TO SPECIALTY

Sales contribution from Non-commoditized segments increasing from 40% to 54%



Source: Company, MNCL Research

**New Capex Plan  
INR 900crs**



Source: Company, MNCL Research

EBITDA contribution from Non-commoditized segments >70%

Particulars	FY20	FY21	FY22E	FY23E
Specialty Chemicals	55.0%	42.3%	43.4%	50.0%
Nutrition	22.0%	20.5%	21.5%	22.4%
Life Science Chemicals	23.0%	37.2%	35.1%	27.5%

Source: Company, MNCL Research

- Given the margin profile, volatility and customer relationships; we believe that Life Science Chemicals business is commoditised in nature.
- Even as Vitamin B3 remains a commodity, we believe it's a better quality business on account of the inherent advantages that Ingrevia enjoy due to Beta pacoine backward integration which ensures much better margin profile.
- We believe that Ingrevia has been focusing away from commoditised business which is reflecting in their sales and EBITDA mix.
- Sales Mix:** from 60% commodity contribution in FY19 to 46% in FY23E
- EBITDA Mix:** >70% EBITDA is contributed from non-commoditised business
- New Capex:** INR 650crs of INR 900crs is earmarked towards non-commoditised business. Of Which Diketene to be live in Q3FY22 while CDMO is gaining traction amongst agrochem clients




# SPECIALTY CHEMICALS


- Revenue grew in Q4FY21 by 17% on YoY basis driven by higher volume. While almost flattish on an annual base
- Margin stood at 21.1% lower vs 22.6% in Q4'FY20; which as per the management is on account of MEIS discontinuance
- Blended EBITDA margins for FY21 stood at 24% vs 21% in FY20
- Specialty Chemicals revenue in Q4FY21 grew driven by growth in Fine chemical and new CDMO projects
- Maintained our global leading positions in Pyridine & II Derivatives. In four products we further improved our global market share in FY21
- Six new products have been commercialized in FY21 incl. Chromium and Zinc Picolinates for Health Supplements for US market

## Pyridine Pricing

- Paraquat ban in Brazil and Thailand resulted in lower demand of Pyridine, which resulted in lower prices during the quarter; however towards the end of Q4FY21 - pricing improved
- As per the management, Pyridine prices should improve on the back of market consolidation and availability of beta pacolines
- We believe increasing Pyridine usage in non Paraquat products and removal of ADD by China remain key pricing tailwinds for the segment
- Beta Pacolines continue to enjoy better pricing due to strong demand from end user segments



Source: Company, MNCL Research



Source: Company, MNCL Research

# ENTERING DIKETENE



## Ingrevia to start commercial production on Diketene in Q3FY22

- Company to start commercial production from Gajraula plant; to further invest in a new facility as a part of Phase 2 of Diketene entry
- Ingrevia intended to launch of 6 Diketene derivatives during the March analyst call. Subsequently, add 8 value-added Diketene derivatives
- It already has expertise in Ketene based chemistry (Life Sciences business) which it is looking to leverage both for the domestic and for export market


## Diketene Industry

- Domestic Diketene market was valued to be ~USD150mn in 2019, of which 40% is imported into India
- Laxmi Organics is the only manufacturer of Diketene Derivatives in India (post purchase of Diketene portfolio from Clariant Chemicals in 2011)
- Major global competitors are Lonza Group, Eastman Chemicals and Nantong Acetic Acid.

## Pricing Disruption less likely as export remains lucrative

- We believe, Kodak has exited Diketene market in India and many other geographies which should help Ingrevia to capture higher market share with reduced pricing impact
- Ingrevia already has interest from multiple International Agro Chem and CDMO clients for their Diketene Derivatives

India's USD 150mn Diketene market breakup; ~40% import dependency



Source: Company, MNCL Research


# NUTRITION




- Revenue in Q4FY21 grew by 22% on YoY basis; 17% growth in FY21 on YoY basis
- EBIDTA Margin stood at 21.4% vs 23.9% in Q4'FY20 which as per the management is on account of MEIS discontinuance
- EBITDA margins for FY21 stood at 19% vs 18% in FY18
- Q4FY21 EBITDA margins were supported by robust pricing environment in Vitamin B3 and higher contribution from Animal nutrition business

## Outlook

- Vitamin B3 - Focus is on Value added segment in Food, Cosmetics etc; adding capacity through de-bottlenecking and fresh investments.
- Animal Nutrition and Health business have achieved higher volumes of Choline chloride and Speciality premixes
- We believe, Ingrevia would continue to do well in the segment due to backward integration in Beta pacolines.
- Availability of Beta pacolines, where Ingrevia has one of the largest global capacity, has been a key bottleneck for many global suppliers.
- Increasing Pre-mixes share and value-added contribution to help in further margin expansion.



Source: Company, MNCL Research



Source: Company, MNCL Research



# LIFE SCIENCE CHEMICALS


- Revenue in Q4FY21 grew by 46% on YoY basis; while for FY21 went up by 13% on YoY basis
- EBITDA margins in Q4FY21 at 19.1% vs 4% last year; FY21 EBITDA margins at 13.6%
- Robust margin expansion was led by Acetyl pricing being at all time high with Acetic acid remaining flattish on a YoY basis
- Expanded capacity (1 lakh to 1.45 lakh TPA of acetic anhydride) and higher utilization(>90%) helped ingrevia to benefit from from the increased demand in Acetyls

## Outlook


- Management continue to remain positive on the pricing over short term given that many China based Acetyls players have vacated the market
- While on the demand side disruptions have happened due to higher inventory hoarding on few APIs including Paracetamol which has seen increased consumption in the run-up to vaccinations / Covid treatment

## Our Assessment

- We believe that pricing environment can remain bullish during H1FY22. As at June, Pricing continue to remain at their peaks
- There has been a lot of consolidation in global Life Science players with Lonza selling their LSC business to Bain, Vertellus Group also selling their LSC business in a private market transaction. Blue sky policy compelled smaller players to shut shops with higher compliance cost in an already thin margin business.
- These factors would lead to better overall pricing in a stable Acetic acid scenario.




Source: Company, MNCL Research




Source: Company, MNCL Research


# FINANCIALS




Source: Company, MNCL Research



Source: Company, MNCL Research



Source: Company, MNCL Research



Source: Company, MNCL Research





# VALUATIONS



## Bull Case

Probability 20%

FY23E  
EBITDA

INR 912crs

EV / EBITDA (x)

18x

Target Price

INR 1015

Triggers

- Continued demand side disruption on Acetyls with favorable RM pricing
- Faster ramp up CDMO business

Our Analysis

Ramp up of Diketene and CDMO business is faster than what we anticipated. Further entry into value-added business in Spec Chem and Nutrition insulates Ingrevia from product / pricing shocks.

Spec Chem to get a major boost with Ingrevia entering Diketene by Q3FY22E and faster ramp-up of CDMO business. New capex initiatives into superior segments such as Diketene, CDMO, Pre-mixes to improve its overall margins profile.

On account of the above, we believe Ingrevia has sufficient room to grow its profitability and improving business profile is deserving of higher multiples.

We thus revise our Mar-22 target price from INR 420 in base case to INR 770 valuing at 15x EV/EBITDA, which implies 35% upside on the CMP. Our Bull / Bear case TP is at INR 1015 and INR 453 respectively.

## Base Case

Probability 60%

INR 840crs

15x

INR 770

- Continued demand side disruption on Acetyls with favorable RM pricing in at least H1FY22



## Bear Case

Probability 20%

INR 746crs

10x

INR 453

- Delay in ramp up of Spec Chem
- Product specific shocks (Pyridine / Vitamin B3)
- Acetyls pricing normalize faster than anticipated

# RISKS



## Volatility in Acetic Acid prices / Vitamin B3 Prices

- China produces ~5.7 MMT of Acetic Acid and is the largest supplier with a share of 42% with a total installed capacity of is 6.5 MMT (FY2019). India produced ~ 160 KT of Acetic Acids during FY2019; India is majorly an import dependent economy for Acetic Acid.
- The prices of Acetic Acid tend to be extremely volatile and given this remains one of the core input, Company is exposed to pricing risk and supply side constraints which can have meaningful impact on its operations.
- There are significant overcapacities in the Vitamin B3 market, specifically in China which triggers a lot of pricing pressure on the product

**Probability : Medium to High**

**Impact : High**

## Competition

- Ingrevia is one of the dominant players in Acetyls and also entering Diketene Derivatives segment. It competes with global and domestic players in both the segment.
- Higher competitive intensity is likely to impact the overall margins in the segment.

**Probability : Medium**

**Impact : Medium**

## Product recalls / Ban

- Any adverse impact on its client end product, has a potential impact on the operations. Company has been previously impacted on account of product specific bans / recalls (Paraquat).
- Company has however, consciously diversified both in terms of products and clients in order to de-risk from such adverse events.

**Probability : Medium**

**Impact : Low**

# SEGMENTAL



Particulars (INR in Crs)	FY16	FY17	FY18	FY19	FY20	FY21	FY22E	FY23E
Specialty Chemicals	1,095	939	977	1,011	1,117	1,124	1,349	1,646
% Sales	38%	35%	29%	29%	35%	32%	34%	36%
YoY Growth	NA	-14%	4%	4%	10%	1%	20%	22%
Nutrition	495	464	566	411	537	630	725	833
% Sales	17%	17%	17%	12%	17%	18%	18%	18%
YoY Growth	NA	-6%	22%	-27%	31%	17%	15%	15%
Life Science Chemicals	1,293	1,311	1,822	2,123	1,525	1,738	1,947	2,141
% Sales	45%	48%	54%	60%	48%	50%	48%	46%
YoY Growth	NA	1%	39%	17%	-28%	14%	12%	10%
<b>Total Sales</b>	<b>2,882</b>	<b>2,714</b>	<b>3,365</b>	<b>3,545</b>	<b>3,179</b>	<b>3,492</b>	<b>4,020</b>	<b>4,620</b>
YoY Growth	NA	-6%	24%	5%	-10%	10%	15%	1%
<b>EBITDA</b>	<b>434</b>	<b>434</b>	<b>632</b>	<b>445</b>	<b>431</b>	<b>612</b>	<b>761</b>	<b>840</b>
<b>EBITDA Margins</b>	<b>15%</b>	<b>16%</b>	<b>19%</b>	<b>13%</b>	<b>14%</b>	<b>18%</b>	<b>19%</b>	<b>18%</b>
YoY Growth	NA	0%	46%	-30%	-3%	42%	24%	10%

Source: Company, MNCL Research

Particulars (INR in Crs)	Q4FY20	Q4FY21	9MFY21	FY20	FY21	FY22E	FY23E
Specialty Chemicals	64	69	199	237	268	337	428
EBITDA Margins	23%	21%	24%	21%	24%	25%	26%
Nutrition	39	43	87	95	130	167	192
EBITDA Margins	24%	22%	20%	18%	21%	23%	23%
Life Science Chemicals	15	105	131	99	236	273	236
EBITDA Margins	4%	19%	11%	6%	14%	14%	11%

Source: Company, MNCL Research

# QUARTERLY



Particulars (INR in crs)	Q1FY19	Q2FY19	Q3FY19	Q4FY19	Q1FY20	Q2FY20	Q3FY20	Q4FY20	Q1FY21	Q2FY21	Q3FY21	Q4FY21
<b>Specialty Chem</b>	<b>235</b>	<b>196</b>	<b>252</b>	<b>328</b>	<b>279</b>	<b>259</b>	<b>293</b>	<b>286</b>	<b>260</b>	<b>255</b>	<b>303</b>	<b>329</b>
<i>QoQ Growth</i>		-17%	29%	30%	-15%	-7%	13%	-2%	-9%	-2%	19%	9%
<i>% of Sales</i>	28%	22%	28%	36%	35%	34%	37%	35%	35%	33%	34%	31%
<b>Nutrition</b>	<b>89</b>	<b>107</b>	<b>106</b>	<b>109</b>	<b>136</b>	<b>113</b>	<b>124</b>	<b>163</b>	<b>149</b>	<b>125</b>	<b>157</b>	<b>199</b>
<i>QoQ Growth</i>		20%	-1%	3%	25%	-17%	10%	31%	-9%	-16%	26%	27%
<i>% of Sales</i>	10%	12%	12%	12%	17%	15%	16%	20%	20%	16%	18%	18%
<b>Life Science Chemicals</b>	<b>524</b>	<b>584</b>	<b>541</b>	<b>475</b>	<b>390</b>	<b>380</b>	<b>381</b>	<b>374</b>	<b>329</b>	<b>403</b>	<b>433</b>	<b>549</b>
<i>QoQ Growth</i>		11%	-7%	-12%	-18%	-3%	0%	-2%	-12%	22%	7%	27%
<i>% of Sales</i>	62%	66%	60%	52%	48%	51%	48%	45%	45%	51%	48%	51%
<b>Total Sales</b>	<b>848</b>	<b>887</b>	<b>899</b>	<b>912</b>	<b>805</b>	<b>752</b>	<b>798</b>	<b>823</b>	<b>738</b>	<b>783</b>	<b>893</b>	<b>1077</b>
<i>QoQ Growth</i>		5%	1%	1%	-12%	-7%	6%	3%	-10%	6%	14%	21%
<b>EBITDA</b>	<b>109</b>	<b>109</b>	<b>126</b>	<b>101</b>	<b>122</b>	<b>91</b>	<b>100</b>	<b>118</b>	<b>124</b>	<b>139</b>	<b>155</b>	<b>200</b>
<i>EBITDA Margins %</i>	13%	12%	14%	11%	15%	12%	13%	14%	17%	18%	17%	19%

Source: Company, MNCL Research

# KTA'S – Q4FY21 CONCALL



## Life Science Chemicals

- Pricing environment in Acetyls extremely good; may continue over short term
- Utilization at >90% in most of the plants, investing in de-bottlenecking which should aid growth
- Higher margins vs peers on account of better process technology, scale and extent of integration

## Specialty Chemicals

- Paraquat ban in Brazil and Thailand impacted prices; however prices stabilized end of Q4FY21
- Commercial production of Diketene in Q3FY22; Have active interest from many clients for value added business.
- Pricing in Diketene should be stable, focus more on Export business where will service CDMO / AgroChem clients.
- Top-line growth in Spec Chem was driven by new CDMO projects addition both on Agro-Chem and Pharmaceuticals side.

## Nutrition Business

- Vitamin B3 pricing is strong, focus is on value added segments including Pharmaceuticals / Cosmetics etc; adding capacity through de-bottlenecking and fresh investments.
- In cosmetics the company expects to increase market share and in pharma wants to be USFDA auditable in 12-14 months
- Animal nutrition segment contributed to growth in Q4FY21; momentum likely to continue

## Agro-Active Subsidiary

- Subsidiary Acquired in Bharuch SEZ to get into Agro-active business planning capex investment this year and it will be functional by 12-24 months
- New subsidiary formed for better tax advantage and will entail total investment of INR 200crs

## Capex Plans

- Capex expenditure for FY21 was 122cr; FY22 to be INR 350crs
- New Capex to be live in 12-18 months
- Existing plants working 85-90% capacity utilisation; thus de-bottlenecking and new capex to aid growth

## Income Tax Rates

- INR 160crs of MAT credit hence ETR will be >30% for 2 years before reverting to lower tax rates
- Cash tax rates will be ~17%

# FINANCIALS



Profit and Loss (INR in Crs)	FY20	FY21	FY22E	FY23E
<b>Revenue</b>	<b>3,178.6</b>	<b>3,492.0</b>	<b>4,019.8</b>	<b>4,619.9</b>
Cost of Materials Consumed	1,681.0	1,688.0	2,122.5	2,457.8
Purchase of Stock in Trade	122.0	99.0		
Changes in Inventory	(118.0)	49.0		
Gross Profit	1,493.6	1,656.0	1,897.4	2,162.1
Gross Profit %	47%	47%	47%	47%
Employee Benefit Expense	284.0	299.0	328.9	378.2
% Sales	9%	9%	8%	8%
Power and Fuel Expense	362.0	324.0	373.0	428.7
% Sales	11%	9%	9%	9%
Other Expenses	448.0	420.0	434.1	515.2
% Sales	14%	12%	11%	11%
<b>EBITDA</b>	<b>399.6</b>	<b>613.0</b>	<b>761.4</b>	<b>840.0</b>
<b>EBITDA %</b>	<b>13%</b>	<b>18%</b>	<b>19%</b>	<b>18%</b>
Depreciation	122.0	125.0	132.6	157.1
EBIT	277.6	488.0	628.8	682.9
EBIT %	9%	14%	16%	15%
Other Income	10.0	15.0	10.0	10.0
Finance Cost	88.0	71.0	35.0	25.0
Profit Before Tax	199.6	432.0	603.8	667.9
Exceptional Item	(2.0)	(13.0)	-	-
Total Tax Expenses	(23.0)	102.0	181.1	200.4
ETR	-12%	24%	30%	30%
<b>Profit After Tax</b>	<b>220.6</b>	<b>317.0</b>	<b>422.6</b>	<b>467.5</b>
<b>Profit After Tax %</b>	<b>7%</b>	<b>9%</b>	<b>11%</b>	<b>10%</b>
EPS	13.8	19.8	26.5	29.4

Balance Sheet (INR in Crs)	FY21	FY22E	FY23E
Property Plant and Equipment	1,745	1,692	1,805
Intangible Assets	11	11	11
Right of Use Assets	49	49	49
Capital Work in Progress	63	333	413
Other Financial Assets	52	52	52
Other Non Current Assets	15	15	15
<b>Total Non Current Assets</b>	<b>1,955</b>	<b>2,172</b>	<b>2,365</b>
Inventories	609	726	834
Trade Receivables	471	446	502
Cash and Cash Equivalents	117	67	142
Other Financial Assets	66	66	66
Other Current Assets	159	183	210
<b>Total Current Assets</b>	<b>1,424</b>	<b>1,490</b>	<b>1,756</b>
<b>Total Assets</b>	<b>3,379</b>	<b>3,662</b>	<b>4,122</b>
Share Capital	16	16	16
Reserves and Surplus	1,907	2,282	2,702
Shareholders Funds	1,923	2,298	2,718
Long Term Borrowings	456	306	206
Deferred Tax Liability	28	28	28
<b>Total Non Current Liabilities</b>	<b>561</b>	<b>411</b>	<b>311</b>
Trade Payables	694	726	834
Other Financial Liabilities	158	181	208
Other Current Liabilities	23	27	31
<b>Total Current Liabilities</b>	<b>894</b>	<b>953</b>	<b>1,093</b>
<b>Total Liabilities</b>	<b>3,379</b>	<b>3,662</b>	<b>4,122</b>

Source: Company, MNCL Research

Source: Company, MNCL Research

# FINANCIALS



Returns Ratios	FY21	FY22E	FY23E
ROCE	19.64%	23.21%	22.55%
ROE	16.49%	18.39%	17.20%
ROA	14.44%	17.17%	16.57%
Margin Ratios	FY21	FY22E	FY23E
EBITDA Margin	17.55%	18.94%	18.18%
Pretax Margin	12.37%	15.02%	14.46%
Net profit Margin	9.08%	10.51%	10.12%
Effective Tax rate	23.61%	30.00%	30.00%
Cash Flow Ratios	FY21*	FY22E	FY23E
CFO/Revenue	0.19	0.17	0.14
Cash Return on Assets (CFO/Average Assets)	0.20	0.19	0.16
Cash Return on Equity (CFO/Average Equity)	0.35	0.30	0.24
Cash to Income (CFO/Operating Income)	1.39	1.08	0.94
Turnover Ratios	FY21	FY22E	FY23E
Total Asset Turnover	1.03	1.10	1.12
Fixed Asset Turnover	1.93	2.29	2.48
Activity Ratios	FY21	FY22E	FY23E
Receivable Days	49.23	40.51	39.70
Payable Days	72.55	65.90	65.90
Inventory Days	63.67	65.90	65.90
Cash Conversion Cycle	40.35	40.51	39.70
Liquidity Ratios	FY21	FY22E	FY23E
Working Capital	521	602	681
Working Capital as % of Revenue	14.93%	14.97%	14.75%
Operating Working Capital	386	446	502
Operatin WC as % of Revenue	11.06%	11.10%	10.88%

Source: Company, MNCL Research

\*2 months of Q4FY21 - CFI / CFF from reported nos. While CFO from presentation for full year FY21.

Cash Flow Statement (INR in Crs)	FY22E	FY23E
Profit before tax	604	668
Depreciation	133	157
Interest expense	35	25
Other income	10	10
Δ in working capital	(57)	(52)
<b>Cash flow from operating activities</b>	<b>679</b>	<b>644</b>
Capex	(305)	(407)
<b>Cash flow from investing activities</b>	<b>(295)</b>	<b>(397)</b>
Repayment of borrowings	(150)	(100)
<b>Cash flow from financing activities</b>	<b>(433)</b>	<b>(173)</b>
<b>Δ in cash and cash equivalents</b>	<b>(49)</b>	<b>74</b>
<b>Cash @ beginning of period</b>	<b>117</b>	<b>67</b>
<b>Cash @ end of period</b>	<b>67</b>	<b>142</b>

Source: Company, MNCL Research

# Thank You!

**Disclaimer:** Monarch Network Capital Limited (hereinafter MNCL), a publically listed company, is engaged in services of retail broking, credits, portfolio management and marketing investment products including mutual funds, life & general insurance and as such prepares and shares research data and reports periodically with clients, investors, stake holders and general public in compliance with Securities and Exchange Board of India Act, 1992, Securities And Exchange Board Of India (Research Analysts) Regulations, 2014 and/or any other applicable directives, instructions or guidelines issued by the Regulators from time to time.

Research report is a written or electronic communication that includes research analysis, research recommendation or an opinion concerning securities or public offer, providing a basis for investment decisions. The views expressed therein are based solely on information available publicly/internal data/other reliable sources believed to be true. The information is provided merely as a complementary service and do not constitute an offer, solicitation for the purchase or sale of any financial instruments, inducement, promise, guarantee, warranty, or as an official confirmation of any transactions or contract of any kind.

Research data and reports published/ emailed/ text messaged via Short Messaging Services, Online Messengers, WhatsApp etc/transmitted through mobile application/s, including but not limited to FLIP™, Video Widget, telephony networks, print or electronic media and or those made available/uploaded on social networking sites (e.g. Facebook, Twitter, LinkedIn etc) by MNCL or those recommendation or offers or opinions concerning securities or public offer which are expressed as and during the course of "Public Appearance" are for informational purposes only. The reports are provided for assistance and are not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Though disseminated to clients simultaneously, not all clients may receive the reports at the same time. MNCL will not treat recipients as clients by virtue of their receiving this report.

The reports include projections, forecasts and other predictive statements which represent MNCL's assumptions and expectations in the light of currently available information. These projections and forecasts are based on industry trends, circumstances and factors which involve risks, variables and uncertainties. The actual performance of the companies represented in the report may vary from those projected. The projections and forecasts described in this reports should be evaluated keeping in mind the fact that these-

- are based on estimates and assumptions
- are subject to significant uncertainties and contingencies
- will vary from actual results and such variations may increase over a period of time
- are not scientifically proven to guarantee certain intended results
- are not published as a warranty and do not carry any evidentiary value.
- are not based on certain generally accepted accounting principles
- are not to be relied on in contractual, legal or tax advice.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Reports based on technical analysis is focused on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

Though we review the research reports for any untrue statements of material facts or any false or misleading information, we do not represent that it is accurate or complete and it should not be relied on in connection with a commitment or contract whatsoever. Because of the possibility of human, technical or mechanical error by our sources of transmission of Reports/Data, we do not guarantee the accuracy, adequacy, completeness or availability of any information and are not to be held responsible for any errors or omissions or for the results obtained from the use of such information. MNCL and/or its Affiliates and its officers, directors and employees including the analysts/authors shall not be in any way responsible for any indirect, special or consequential damages that may arise to any person from any inadvertent error in the information contained in the reports nor do they take guarantee or assume liability for any omissions of the information contained therein. Information contained therein cannot be the basis for any claim, demand or cause of action. These data, reports and information do not constitute scientific publication and do not carry any evidentiary value whatsoever.

The reports are not for public distribution. Reproduction or dissemination, directly or indirectly, of research data and reports of MNCL in any form is prohibited except with the written permission of MNCL. Persons into whose possession the reports may come are required to observe these restrictions. Opinions expressed therein are our current opinion as of the date appearing on the report only. Data may be subject to update and correction without notice. While we endeavour to update on a reasonable basis the information discussed in the reports, there may be regulatory, compliance, or other reasons that prevent us from doing so.

The reports do not take into account the particular investment objectives, financial situations, risk profile or needs of individual clients. The user assumes the entire risk of any use made of this information. Each recipient of the reports should make such investigation as deemed necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in such reports (including the merits and risks involved).

Certain transactions - futures, options and other derivatives as well as non-investment grade securities - involve substantial risks and are not suitable for all investors. Investors may lose his/her entire investment under certain market conditions. Before acting on any advice or recommendation in this material, investors should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. The price and value of investments referred to in research reports and the income from them may fluctuate. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options. Foreign currencies denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. Investors in securities such as ADRs, the value of which are influenced by foreign currencies effectively assume currency risk.

The recommendations in the reports are based on 12 month horizon, unless otherwise specified. The investment ratings are on absolute positive/negative return basis. It is possible that due to volatile price fluctuation in the near to medium term, there could be a temporary mismatch to rating. For reasons of valuations/return/lack of clarity/event we may revisit rating at appropriate time. The stocks always carry the risk of being upgraded to buy or downgraded to a hold, reduce or sell. The opinions expressed in the reports are subject to change but we have no obligation to tell our clients when our opinions or recommendations change. The reports are non-inclusive and do not consider all the information that the recipients may consider material to investments. The reports are issued by MNCL without any liability/undertaking/commitment on the part of itself or any of its entities.

Recipients of the research reports should assume that entities of MNCL may receive commission, brokerage, fees or other compensation from the company or companies that are the subject of the reports. We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of reports/data/material, may, from time to time have 'long' or 'short' positions in, act as principal in, and buy or sell the securities thereof of companies mentioned therein or be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as market maker in the financial instruments of the company/ies discussed therein or act as advisor or lender/borrower to such company/ies or have other potential conflicts of interests with respect to any recommendation and related information and opinions.

We further undertake that-

- No disciplinary action has been taken against the research analyst or MNCL by any authority in connection with their respective business activity.
- MNCL, Research analysts, persons reporting to research analysts and their relatives may have financial interests and material conflict of interest in the subject company.
- MNCL, Research analysts, persons reporting to research analysts and their relatives may have actual/beneficial ownership of 1% or more in the subject company's securities, at the month immediately preceding the date of publication of this research report.

Past performance is not a guide for future performance, future returns are not guaranteed and investors may suffer losses which may exceed their original capital. The securities described herein may not be eligible for sale in all jurisdictions or to all categories of investors. The countries in which the companies mentioned in this report are organized may have restrictions on investments, voting rights or dealings in securities by nationals of other countries. Distributing/taking/sending/dispatching/transmitting this document in certain foreign jurisdictions may be restricted by law, and persons into whose possession this document comes should inform themselves about, and observe any such restrictions. Failure to comply with this restriction may constitute a violation of any foreign jurisdiction laws.

The user should consult their own advisors to determine the merits and risks of investment and also read the Risk Disclosure Documents for Capital Markets and Derivative Segments as prescribed by Securities and Exchange Board of India before investing in the Indian Markets.

Analyst holding in stock: **NO**

## Key to MNCL Investment Rankings

Buy: Upside by >15%, Accumulate: Upside by 5% to 15%, Hold: Downside/Upside by -5% to +5%, Reduce: Downside by 5% to 15%, Sell: Downside by >15%

**Monarch Network Capital Ltd. (www.mnclgroup.com)**

**Office:** - 9th Floor, Atlanta Centre, Sonawala Lane, Opp. Udyog Bhavan, Goregaon (E), Mumbai 400 063. Tel No.: 022 30641600